-5%
Famotidine is a histamine H2-receptor antagonist. Famotidine completely inhibits the action of histamine on H2- receptors of parietal cells. It inhibits basal, overnight, and pentagastrin-stimulated gastric acid secretion. The H2- receptor antagonist activity of Famotidine is slowly reversible, since the drug dissociates slowly from the H2-receptor
Famas is indicated in-
- Gastric ulcer
- Duodenal ulcer
- Anastomotic ulcer
- Acute stress ulcer
- Reflux esophagitis and
- Zollinger-Ellison syndrome.
Famas is also indicated for the treatment of acute gastritis and chronic gastritis in the acute exacerbation stage.
Tablet:
- For gastric ulcer, duodenal ulcer, anastomotic ulcer, upper gastrointestinal hemorrhage, reflux esophagitis, and Zollinger-Ellison syndrome: Usual dose for adults: Famotidine 20 mg twice daily (after breakfast and after supper or before bedtime) or Famotidine 40 mg can be administered orally once daily at bedtime.
- For the treatment of acute gastritis, chronic gastritis in acute exacerbation stage: Usual dosage for adults is Famotidine 20 mg orally twice a day (after breakfast and after supper or before bedtime). Also, Famotidine 40 mg can be orally administered once a day (before bedtime), dosage should be adjusted according to age and symptoms. Most ulcer patients heal within 4-8 weeks. For maintenance therapy, the recommended oral dose is 20 mg once daily. Or, as directed by the registered physician.
No clinically important drug interactions have been identified. Famas does not interact with the cytochrome P450-linked drug-metabolizing enzyme system.
Pregnancy category B. There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Caution should be exercised when Famotid is administered to a nursing woman.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.